Circulating suPAR associates with severity and in‐hospital progression of COVID‐19

Background COVID‐19 disease progression is characterized by hyperinflammation and risk stratification may aid in early aggressive treatment and advanced planning. The aim of this study was to assess whether suPAR and other markers measured at hospital admission can predict the severity of COVID‐19....

Full description

Saved in:
Bibliographic Details
Published in:European journal of clinical investigation 2022-07, Vol.52 (7), p.e13794-n/a
Main Authors: Chalkias, Athanasios, Skoulakis, Anargyros, Papagiannakis, Nikolaos, Laou, Eleni, Tourlakopoulos, Konstantinos, Pagonis, Athanasios, Michou, Anastasia, Ntalarizou, Nicoletta, Mermiri, Maria, Ragias, Dimitrios, Bernal‐Morell, Enrique, Cebreiros López, Iria, García de Guadiana‐Romualdo, Luis, Eugen‐Olsen, Jesper, Gourgoulianis, Konstantinos, Pantazopoulos, Ioannis, Kampolis, Christos, Albaladejo‐Otón, María Dolores, Rodríguez Mulero, María Dolores, Galindo Martínez, María, Hernández Olivo, Marta, Campos Rodríguez, Valerio, Arnaldos Carrillo, María, Noguera Velasco, Jose Antonio, Pascual Figal, Domingo A, Alcaraz García, Antonia, Alcaraz García, María José, Martínez Martínez, Mónica, Esteban‐Torrella, Patricia, Sancho‐Rodríguez, Natalia
Format: Article
Language:English
Subjects:
Age
Albumin
COVID-19
Enzyme-linked immunosorbent assay
Epidermal growth factor receptors
Ferritin
Interleukin 6
L-Lactate dehydrogenase
Lactate dehydrogenase
Lactic acid
Markers
Observational studies
Original
outcome
Patients
Procalcitonin
Serum albumin
suPAR
Survival
WHO Clinical Progression Scale
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background COVID‐19 disease progression is characterized by hyperinflammation and risk stratification may aid in early aggressive treatment and advanced planning. The aim of this study was to assess whether suPAR and other markers measured at hospital admission can predict the severity of COVID‐19. Methods The primary outcome measure in this international, multi‐centre, prospective, observational study with adult patients hospitalized primarily for COVID‐19 was the association of WHO Clinical Progression Scale (WHO‐CPS) with suPAR, ferritin, CRP, albumin, LDH, eGFR, age, procalcitonin, and interleukin‐6. Admission plasma suPAR levels were determined using the suPARnostic® ELISA and suPARnostic® Turbilatex assays. Results Seven hundred and sixty‐seven patients, 440 (57.4%) males and 327 (42.6%) females, were included with a median age of 64 years. Log‐suPAR levels significantly correlated with WHO‐CPS score, with each doubling of suPAR increasing the score by one point (p 
ISSN:0014-2972
1365-2362
DOI:10.1111/eci.13794